

OpioiD mu receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/OA20E86AAEFFEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: OA20E86AAEFFEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "OpioiD mu receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in OpioiD mu receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

OpioiD mu receptor antagonists Understanding

OpioiD mu receptor antagonists: Overview

The μ opioiD receptor (MOR) is a prominent member of the G protein-coupled receptor family and the molecular target of morphine and other opioiD drugs. OpioiD mu receptors consist of a single polypeptide chain possessing an extracellular N-terminal region, seven transmembrane domains, and an intracellular C-terminal tail. The mu opioiD antagonists, naloxone and naltrexone are used clinically as rescue medications for opioiD related intoxication. The receptor acts as a main pharmacological target for the management of moderate to severe pain, and is of therapeutic value for the treatment of drug abuse, alcohol abuse, and gastrointestinal motility dysfunction. The

Opioid mu receptor antagonists based therapies are under investigation for the treatment of opioid induced pruritus of the skin, obesity, and Parkinson-induced tardive dyskinesia.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Opioid mu receptor antagonists R&D. The therapies under development are focused on novel approaches for Opioid mu receptor antagonists.

Opioid mu receptor antagonists Emerging Drugs Chapters

This segment of the Opioid mu receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Opioid mu receptor antagonists Emerging Drugs

FMXIN-001: Nasus Pharma

FMXIN001 is a combination drug device using Aptar Pharma's Unidose Powder device. Each single use device contains 4 mg of Naloxone powder. The active compound's shape, size, and morphology in combination with a device provides rapid and precise delivery of the drug to the blood stream. The potential therapy is in Phase II clinical developmental studies for the treatment opioid-related disorders.

LT5001: Lumosa Therapeutics

LT5001 drug product is a kappa-opioid agonist and partial mu-opioid antagonist and developed as a topical ointment formulation, which is thought to have the potential to modulate peripheral opioid receptors present on sensory nerves and immune cells. The drug is in Phase I/II clinical studies for the treatment of Pruritus.

Further product details are provided in the report.....

Opioid mu receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Opioid mu receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Opioid mu receptor antagonists

There are approx. 15+ key companies which are developing the Opioid mu receptor antagonists. The companies which have their Opioid mu receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Nasus Pharma.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Opioid mu receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Opioid mu receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Opioid mu receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid mu receptor antagonists drugs.

Opioid mu receptor antagonists Report Insights

- Opioid mu receptor antagonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Opioid mu receptor antagonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Opioid mu receptor antagonists drugs?

How many Opioid mu receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Opioid mu receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid mu receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Opioid mu receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tonix Pharmaceuticals

Bridge therapeutics

ChironWells

Avior Bio

Lumosa Therapeutics

Nasus Pharma

Orexo

Progenics Pharmaceuticals

Trevi Therapeutics

Chiesi Farmaceutici

Alkermes

Shionogi

Key Products

TNX 601

BT 219

Research programme: gastrointestinal disorder therapeutics

AV103

LT-5001

FMXIN-001

OX 124

Methylnaltrexone bromide

T 111

Buprenorphine

ALKS-3831

Naldemedine

I would like to order

Product name: Opioid mu receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/OA20E86AAEFFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OA20E86AAEFFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970